Robot-based Therapy for Upper Limb Sensorimotor Impairments After Stroke

Sponsor
KU Leuven (Other)
Overall Status
Completed
CT.gov ID
NCT05007002
Collaborator
Universitaire Ziekenhuizen Leuven (Other)
10
1
1
11
0.9

Study Details

Study Description

Brief Summary

After a stroke, more than two out of three patients experience problems with upper limb movement and sensation. Current evidence on treatment of upper limb sensory impairments is scarce and shows unclear results. Robot-based therapy has been increasingly used to treat upper limb motor impairments, with similar positive results as compared to conventional therapy. This study aims to investigate a novel robot-based therapy program for treatment of upper limb sensory impairments. The therapy program consists of 10 one-hour session spread over 4 weeks and will be evaluated for its effect in 20 chronic stroke patients. The investigators hypothesize that a 4-week robot-based therapy program can improve upper limb sensation and movement.

Condition or Disease Intervention/Treatment Phase
  • Device: Robot-based therapy
N/A

Detailed Description

Up to 70% of stroke survivors show upper limb impairments consisting of motor and/or somatosensory impairments. These impairments often persist well into the chronic stage, and may lead to significant limitations in activities of daily living and may negatively affect quality of life. Different interventions have been investigated to treat upper limb motor impairments, including robot-based therapy, which shows similar positive results as compared to conventional therapy. Evidence on interventions for somatosensory impairments is scarce and often of low quality. This study therefore aims to evaluate the effect of a robot-based therapy program on sensorimotor function of the upper limb in a group of 20 chronic stroke patients.

The robot-based therapy will be provided using the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada) and consists of passive and active therapy tasks for proprioception and sensory processing. The therapy consists of 10 one-hour sessions spread over 4 weeks. Clinical and robot-based motor and somatosensory assessments will be performed at 4 time points: twice at baseline, once at mid intervention, and once after 10 hours of therapy. The investigators hypothesize to find improvement in both upper limb motor and somatosensory function after the therapy program. The results from this pilot study will provide a basis for further research.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Robot-based Therapy for Upper Limb Sensorimotor Impairments in the Chronic Phase After Stroke: a Pilot Study
Actual Study Start Date :
Jul 14, 2021
Actual Primary Completion Date :
Jun 13, 2022
Actual Study Completion Date :
Jun 13, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Robot-based therapy

Chronic stroke patients receiving robot-based therapy

Device: Robot-based therapy
Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)

Outcome Measures

Primary Outcome Measures

  1. Kinarm: sensory processing task [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing

Secondary Outcome Measures

  1. Kinarm: arm position matching task [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Assessment of limb position sense using a 9-target mirror-matching task on the Kinarm Exoskeleton Lab

  2. Kinarm: arm movement matching task [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Assessment of limb movement sense using a mirror-matching task on the Kinarm Exoskeleton Lab

  3. Kinarm: visually guided reaching task [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Assessment of motor function using a 4-target centre-out reaching task on the Kinarm End-Point Lab

  4. Kinarm: working memory task [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Assessment of working memory on the Kinarm End-Point Lab, by asking the participant to remember the position of 3, 4, 5 or 6 targets simultaneously.

  5. Erasmus modified Nottingham sensory assessment [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of somatosensory function (including exteroception, proprioception and sensory processing) on an ordinal scale ranging from 0 to 40, with higher scores meaning better performance

  6. Tactile discrimination test [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of sensory processing with an area under the curve based scoring system, with higher scores meaning better performance

  7. Functional tactile object recognition test [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of sensory processing on an ordinal scale ranging from 0 to 42, with higher scores meaning better performance

  8. Fugl-Meyer upper extremity assessment [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of motor function on an ordinal scale ranging from 0 to 66, with higher scores meaning better performance

  9. Action research arm test [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Timed clinical assessment of motor activity performance on an ordinal scale ranging from 0 to 57, with higher scores meaning better performance

  10. Sensorimotor action research arm test [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Timed clinical assessment of sensorimotor performance on an ordinal scale ranging from 0 to 57, with higher scores meaning better performance

  11. Montreal cognitive assessment [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of cognitive function on an ordinal scale ranging from 0 to 30, with higher scores meaning better performance

  12. Star cancellation test [Change during 4 weeks of therapy provided at least 6 months after stroke]

    Clinical assessment of visuospatial neglect on an ordinal scale ranging from 0 to 54, with higher scores meaning better performance, and a score below 44 indicating the presence of visuospatial neglect

  13. Kinarm: sensory processing task [Change in 2 baseline measures taken 2 days apart, at least 6 months after stroke]

    Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing

  14. Kinarm: sensory processing task [Change during the first 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke]

    Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing

  15. Kinarm: sensory processing task [Change during the last 2 weeks of a 4-week therapy protocol provided at least 6 months after stroke]

    Newly-developed task on the Kinarm End-Point Lab used to assess passive and active sensory processing

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • At least 18 years old

  • A first-ever unilateral, supratentorial stroke (as defined by WHO)

  • In the chronic phase after stroke (i.e. being at least 6 months after stroke)

  • Motor deficits of the upper limb (Fugl-Meyer Motor Assessment - Upper Extremity < 60/66)

  • Somatosensory deficits of the upper limb (Erasmus modified Nottingham Sensory Assessment < 36/40)

  • Ability to perform, at least to some extent, active shoulder abduction and wrist extension against gravity

  • Ability to perform passive and active sensory processing assessment task (primary outcome measure)

Exclusion Criteria:
  • History of previous stroke or TIA

  • Any serious musculoskeletal and/or other neurological conditions

  • Serious communication or cognitive deficits

  • No written informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 KU Leuven Leuven Belgium 3001

Sponsors and Collaborators

  • KU Leuven
  • Universitaire Ziekenhuizen Leuven

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof Geert Verheyden, Professor Neurorehabilitation, KU Leuven
ClinicalTrials.gov Identifier:
NCT05007002
Other Study ID Numbers:
  • S61997[2]
First Posted:
Aug 16, 2021
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prof Geert Verheyden, Professor Neurorehabilitation, KU Leuven
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022